Results from the INFINITY-SWEDEHEART trial showed that Elixir Medical’s drug-eluting coronary implant was noninferior to a drug-eluting stent for target lesion failure at 1 year. The bioadaptable drug-eluting coronary implant is seen as a significant advancement in treating coronary artery disease by restoring vessel natural function. In other cardiology news, researchers found that not fasting before cardiac catheterization procedures with conscious sedation was safe and resulted in better patient satisfaction. Additionally, a study showed that stopping abelacimab may not be necessary before invasive procedures, and the prevalence of atrial fibrillation in U.S. adults is higher than previous estimates. TAVR was found to be superior to surgery for women with severe aortic stenosis at 1 year.
Source link
Implant for coronary artery disease; Fasting vs. no fasting
